Special populations

Schizophrenia and visual impairment

March 26, 2026 9 min read

One of the most discussed findings in modern schizophrenia epidemiology is also one of the most curious: in repeated population studies and case-series reviews, including a widely cited 2018 review by Steven Silverstein and colleagues in Schizophrenia Research, researchers have failed to identify a single confirmed case of schizophrenia in a person blind from birth or very early childhood. The finding has prompted a great deal of speculation about what congenital blindness might be doing — possibly involving compensatory wiring, altered prediction-error processing, or stronger development of certain auditory and language networks. Whether any of those explanations turn out to be right, the observation itself has shaped how researchers think about schizophrenia.

In one sentence

Congenital blindness appears to be strongly protective against schizophrenia, late-onset vision loss can produce vivid visual hallucinations called Charles Bonnet syndrome that are not psychotic, and people who develop schizophrenia and later lose vision face a unique and under-served combination of needs.

The congenital blindness puzzle

The protective association is not absolute proof of causation, and there are real methodological caveats — small populations, possible underdetection, and the difficulty of separating congenital total blindness from low vision. But after decades of looking, the absence of cases is striking. Several hypotheses have been offered:

None of this is settled science. It is, however, generative — and a reminder that the brain is more flexible than the standard model assumes.

Charles Bonnet syndrome: not psychosis

People who lose vision later in life — typically from macular degeneration, diabetic retinopathy, or glaucoma — sometimes experience vivid, complex visual hallucinations: faces, animals, geometric patterns, miniature people. This is called Charles Bonnet syndrome, and it is not a psychotic disorder. Key features:

The National Eye Institute describes the syndrome and emphasises that recognising it prevents misdiagnosis as schizophrenia or dementia. People with Charles Bonnet syndrome do not need antipsychotics. They need reassurance, vision rehabilitation, and sometimes adjustment of lighting and visual environment.

Schizophrenia in people who lose vision later

People who develop schizophrenia in the usual age window and subsequently lose vision face a combination of issues that are often handled poorly:

What good care looks like

Coordination with eye care

Annual eye exams for people on antipsychotics are reasonable, particularly on quetiapine. The American Academy of Ophthalmology outlines monitoring guidance. Sudden vision changes warrant urgent evaluation.

Accessible mental health materials

Large-print medication labels, screen-reader-compatible patient portals, audio versions of psychoeducational material, and accessible apps are not optional — they are required under the ADA for federally funded healthcare. Family members can request these in writing if they are not offered.

Vision rehabilitation as part of treatment

Orientation and mobility training, low-vision aids, and assistive technology help reduce isolation and depression. State commissions for the blind, often funded under the federal Independent Living Services for Older Blind program, provide these services free or low-cost.

Recognising Charles Bonnet syndrome

If a person with vision loss reports new visual hallucinations without other psychotic symptoms and with preserved insight, Charles Bonnet syndrome is the much more likely diagnosis than late-onset schizophrenia. Reassurance, environmental adjustment, and patience usually help more than medication.

Seek care if

Sudden visual changes, eye pain, or loss of vision should prompt an emergency ophthalmology evaluation regardless of psychiatric diagnosis. New visual hallucinations accompanied by paranoia, voices, or loss of insight should be evaluated by a psychiatrist.

The Deaf-Blind population

People who are both Deaf and Blind face the steepest set of barriers in the mental health system. Tactile signing, support service providers (SSPs), and specialised case management are rarely available. The Helen Keller National Center is one of the few national resources.

Resources

See related articles on vision care in schizophrenia, visual hallucinations, and blurred vision on antipsychotics.

The bottom line

Vision and schizophrenia have a relationship that is more complicated than it first appears. The protective effect of congenital blindness is one of psychiatry's open questions. Visual hallucinations in people who lose vision later are usually Charles Bonnet syndrome, not psychosis, and do not need antipsychotics. People who live with both schizophrenia and vision loss deserve care that takes both seriously.


This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.

Frequently asked questions

Do blind people get schizophrenia?
People who lose vision later in life can develop schizophrenia at typical rates. People who are congenitally blind appear to develop schizophrenia at extremely low rates — possibly never, in published case literature — though the reasons are not fully understood.
Are visual hallucinations always psychotic?
No. Charles Bonnet syndrome produces vivid visual hallucinations in people with vision loss, with preserved insight and no other psychotic symptoms. It is not a psychiatric illness and does not require antipsychotics.
Can antipsychotics affect vision?
Some can. Quetiapine has been linked to cataracts at high cumulative doses, and older agents like thioridazine and chlorpromazine can cause retinal pigmentary changes. Annual eye exams are reasonable for people on long-term antipsychotic treatment.

Try Frida — your calm companion

Frida helps people living with schizophrenia track moods, manage medication, and build stability. 7-day free trial.

Get the app →